Cambrex, a contract manufacturer of small-molecule active pharmaceutical ingredients (APIs), is investing in research and development and manufacturing capabilities for generic APIs, at its site in Paullo, Milan, Italy.

The investments include the installation of development and analytical equipment to support the development of highly potent APIs (HPAPIs) as well as a new 2,800-liter hydrogenator and 1,500-mm diameter centrifuge. The company says that it expects all equipment to be installed and validated by the end of 2017.

This investment comes after the installation of a new pilot plant at the Milan site in 2017, and recent announcements of expansions across the Cambrex network of manufacturing sites, including the construction of a $24-million, 4,500-square-foot HPAPI manufacturing facility at its Charles City, Iowa site, which is due to open in 2019.

Source: Cambrex